Imran Manji1, Simon M Manyara2, Beatrice Jakait2, William Ogallo2,3, Isabel C Hagedorn4, Stephanie Lukas2, Eunice J Kosgei2, Sonak D Pastakia2,5. 1. Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya. imranmanji@hotmail.com. 2. Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya. 3. Department of Biomedical Informatics, Columbia University Medical Center, New York, IN, United States. 4. Department of Pharmacy Practice, Butler University, College of Pharmacy and Health Sciences, Indianapolis, IN, United States. 5. Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, United States.
Abstract
OBJECTIVES: A pressing challenge in low and middle-income countries (LMIC) is inadequate access to essential medicines, especially for chronic diseases. The Revolving Fund Pharmacy (RFP) model is an initiative to provide high-quality medications consistently to patients, using revenues generated from the sale of medications to sustainably resupply medications. This article describes the utilization of RFPs developed by the Academic Model Providing Access to Healthcare (AMPATH) with the aim of stimulating the implementation of similar models elsewhere to ensure sustainable access to quality and affordable medications in similar LMIC settings. METHODS: The service evaluation of three pilot RFPs started between April 2011 and January 2012 in select government facilities is described. The evaluation assessed cross-sectional availability of essential medicines before and after implementation of the RFPs, number of patient encounters and the impact of community awareness activities. FINDINGS: Availability of essential medicines in the three pilot RFPs increased from 40%, 36% and <10% to 90%, 94% and 91% respectively. After the first year of operation, the pilot RFPs had a total of 33 714 patient encounters. As of February 2014, almost 3 years after starting up the first RFP, the RFPs had a total of 115 991 patient encounters. In the Eldoret RFP, community awareness activities led to a 51% increase in sales. CONCLUSIONS: With proper oversight and stakeholder involvement, this model is a potential solution to improve availability of essential medicines in LMICs. These pilots exemplify the feasibility of implementing and scaling up this model in other locations.
OBJECTIVES: A pressing challenge in low and middle-income countries (LMIC) is inadequate access to essential medicines, especially for chronic diseases. The Revolving Fund Pharmacy (RFP) model is an initiative to provide high-quality medications consistently to patients, using revenues generated from the sale of medications to sustainably resupply medications. This article describes the utilization of RFPs developed by the Academic Model Providing Access to Healthcare (AMPATH) with the aim of stimulating the implementation of similar models elsewhere to ensure sustainable access to quality and affordable medications in similar LMIC settings. METHODS: The service evaluation of three pilot RFPs started between April 2011 and January 2012 in select government facilities is described. The evaluation assessed cross-sectional availability of essential medicines before and after implementation of the RFPs, number of patient encounters and the impact of community awareness activities. FINDINGS: Availability of essential medicines in the three pilot RFPs increased from 40%, 36% and <10% to 90%, 94% and 91% respectively. After the first year of operation, the pilot RFPs had a total of 33 714 patient encounters. As of February 2014, almost 3 years after starting up the first RFP, the RFPs had a total of 115 991 patient encounters. In the Eldoret RFP, community awareness activities led to a 51% increase in sales. CONCLUSIONS: With proper oversight and stakeholder involvement, this model is a potential solution to improve availability of essential medicines in LMICs. These pilots exemplify the feasibility of implementing and scaling up this model in other locations.
Authors: Benson Njuguna; Susan Vorkoper; Pragna Patel; Mike J A Reid; Rajesh Vedanthan; Colin Pfaff; Paul H Park; Lydia Fischer; Jeremiah Laktabai; Sonak D Pastakia Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Magdalena P Bravo; Meridith Blevins Peratikos; Amina S Muicha; Epifanio Mahagaja; Maria Fernanda Sardella Alvim; Ann F Green; C William Wester; Sten H Vermund Journal: AIDS Res Hum Retroviruses Date: 2020-03-02 Impact factor: 2.205
Authors: M P Ngogang Djobet; David Singhe; Julienne Lohoue; Christopher Kuaban; Jeanne Ngogang; Ernest Tambo Journal: AIDS Res Ther Date: 2017-04-04 Impact factor: 2.250
Authors: Tim Mercer; Adrian Gardner; Benjamin Andama; Cleophas Chesoli; Astrid Christoffersen-Deb; Jonathan Dick; Robert Einterz; Nick Gray; Sylvester Kimaiyo; Jemima Kamano; Beryl Maritim; Kirk Morehead; Sonak Pastakia; Laura Ruhl; Julia Songok; Jeremiah Laktabai Journal: Global Health Date: 2018-05-08 Impact factor: 4.185
Authors: Tim Mercer; Alice C Chang; Lydia Fischer; Adrian Gardner; Immaculate Kerubo; Dan N Tran; Jeremiah Laktabai; Sonak Pastakia Journal: Diabetes Metab Syndr Obes Date: 2019-10-31 Impact factor: 3.168
Authors: Aileen Y Chang; Margaret Mungai; Sarah J Coates; Tiffany Chao; Haji Philip Odhiambo; Phelix M Were; Sara L Fletcher; Toby Maurer; Rakhi Karwa; Sonak D Pastakia Journal: Dermatol Clin Date: 2020-10-31 Impact factor: 3.478
Authors: Aileen Y Chang; Edith C Tonui; Douglas Momanyi; Alex R Mills; Paul Wasike; Rakhi Karwa; Toby A Maurer; Sonak D Pastakia Journal: Dermatol Ther (Heidelb) Date: 2018-06-15
Authors: Tim Mercer; Benson Njuguna; Gerald S Bloomfield; Jonathan Dick; Eric Finkelstein; Jemima Kamano; Ann Mwangi; Violet Naanyu; Sonak D Pastakia; Thomas W Valente; Rajesh Vedanthan; Constantine Akwanalo Journal: Trials Date: 2019-09-09 Impact factor: 2.279